Gubra A/S in 1 story
The narratives GUBRA.CO currently appears in, with its side and exposure in each.
Bull side
1 story- GLP-1 Eats Everything
GUBRA.CO in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
Gubra develops peptide-based obesity drugs, including a long-acting amylin analogue partnered with AbbVie that could complement GLP-1 therapy.
Bear side
0 storiesNo bear-side stories for GUBRA.CO yet.